LCCTF yields 0.67% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, LCCTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LCCTF + JNJ for your $10,000?
L'Occitane International S.A., together with its subsidiaries, designs, manufactures, and retails various natural and organic ingredient-based cosmetics and well-being products. It offers perfumes, soaps, and fragrant products. The company also provides skincare, haircare, body and bath, makeup, floral water, beauty oils, and other products. In addition, it engages in the general warehousing business. The company markets and sells its products under the L'OCCITANE en Provence, Melvita, Erborian, L'Occitane au Brésil, LimeLife by Alcone, ELEMIS, and Sol de Janeiro brand names to final customers, as well as intermediates, such as distributors, wholesalers, TV show channels, and travel retailers. As of March 31, 2022, it operated 3,068 retail locations with 1,490 own retail stores. It also sells its products through online. L'Occitane International S.A. has operations in Japan, the United States, Hong Kong, China, France, Russia, the United Kingdom, Russia, Luxembourg, Brazil, Taiwan, and internationally. The company was founded in 1976 and is headquartered in Luxembourg City, Luxembourg. L'Occitane International S.A. is a subsidiary of L'Occitane Groupe S.A.
Full LCCTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.